Market Research Logo

Osteoarthritis Pain - Pipeline Review, H2 2015

Osteoarthritis Pain - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Osteoarthritis Pain - Pipeline Review, H2 2015’, provides an overview of the Osteoarthritis Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Osteoarthritis Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Osteoarthritis Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Osteoarthritis Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Osteoarthritis Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Osteoarthritis Pain Overview
Therapeutics Development
Pipeline Products for Osteoarthritis Pain - Overview
Pipeline Products for Osteoarthritis Pain - Comparative Analysis
Osteoarthritis Pain - Therapeutics under Development by Companies
Osteoarthritis Pain - Therapeutics under Investigation by Universities/Institutes
Osteoarthritis Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Osteoarthritis Pain - Products under Development by Companies
Osteoarthritis Pain - Products under Investigation by Universities/Institutes
Osteoarthritis Pain - Companies Involved in Therapeutics Development
AbbVie Inc.
Addex Therapeutics Ltd
Afferent Pharmaceuticals, Inc.
Akron Molecules AG
Allergan Plc
Amgen Inc.
Ampio Pharmaceuticals, Inc.
AnaMar AB
Antibe Therapeutics, Inc.
AskAt Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bone Medical Limited
Centrexion Corporation
Convergence Pharmaceuticals Ltd.
Eli Lilly and Company
Elite Pharmaceuticals, Inc.
Flexion Therapeutics, Inc.
Grunenthal GmbH
Iroko Pharmaceuticals, LLC
Nektar Therapeutics
Nuvo Research Inc.
Pfizer Inc.
Phosphagenics Limited
Pozen, Inc.
Purdue Pharma L.P.
Regeneron Pharmaceuticals, Inc.
Rottapharm SpA
Osteoarthritis Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lidocaine hydrochloride + tetracaine hydrochloride) - Drug Profile
(naltrexone hydrochloride + oxycodone hydrochloride) SR - Drug Profile
A-889425 - Drug Profile
AAT-008 - Drug Profile
ADX-71441 - Drug Profile
AF-219 - Drug Profile
AKR-202 - Drug Profile
AMAP-102 - Drug Profile
Ampion - Drug Profile
AQU-010 - Drug Profile
AS-288640100 - Drug Profile
ATB-346 - Drug Profile
BI-1026706 - Drug Profile
calcitonin - Drug Profile
capsaicin - Drug Profile
cebranopadol - Drug Profile
celecoxib - Drug Profile
CGS-125 - Drug Profile
CR-4056 - Drug Profile
CRB-0022 - Drug Profile
CRB-0089 - Drug Profile
duloxetine hydrochloride DR - Drug Profile
ELS-130 - Drug Profile
fasinumab - Drug Profile
fulranumab - Drug Profile
FX-005 - Drug Profile
grapiprant - Drug Profile
ibuprofen - Drug Profile
MEDI-7352 - Drug Profile
naproxen sodium - Drug Profile
NEO-5024 - Drug Profile
NEO-6860 - Drug Profile
NKTR-181 - Drug Profile
OLT-1177 - Drug Profile
onabotulinumtoxin A - Drug Profile
oxycodone ER - Drug Profile
PA-300 DR - Drug Profile
PA-65020 - Drug Profile
Small Molecule to Agonize TRPV1 for Osteoarthritic Pain - Drug Profile
Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain - Drug Profile
Small Molecules to Agonize TRPV1 for Osteoarthritis Pain - Drug Profile
Small Molecules to Block Calcium Ion Channel for Osteoarthritis Pain - Drug Profile
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
Small Molecules to Inhibit PDE2 for Osteoarthritis Pain - Drug Profile
tanezumab - Drug Profile
triamcinolone acetonide sodium phosphate SR - Drug Profile
V-116517 - Drug Profile
VG-201 - Drug Profile
VLNX-4975 - Drug Profile
Osteoarthritis Pain - Recent Pipeline Updates
Osteoarthritis Pain - Dormant Projects
Osteoarthritis Pain - Discontinued Products
Osteoarthritis Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Osteoarthritis Pain, H2 2015
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015
Osteoarthritis Pain - Pipeline by AbbVie Inc., H2 2015
Osteoarthritis Pain - Pipeline by Addex Therapeutics Ltd, H2 2015
Osteoarthritis Pain - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015
Osteoarthritis Pain - Pipeline by Akron Molecules AG, H2 2015
Osteoarthritis Pain - Pipeline by Allergan Plc, H2 2015
Osteoarthritis Pain - Pipeline by Amgen Inc., H2 2015
Osteoarthritis Pain - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015
Osteoarthritis Pain - Pipeline by AnaMar AB, H2 2015
Osteoarthritis Pain - Pipeline by Antibe Therapeutics, Inc., H2 2015
Osteoarthritis Pain - Pipeline by AskAt Inc., H2 2015
Osteoarthritis Pain - Pipeline by Astellas Pharma Inc., H2 2015
Osteoarthritis Pain - Pipeline by AstraZeneca Plc, H2 2015
Osteoarthritis Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Osteoarthritis Pain - Pipeline by Bone Medical Limited, H2 2015
Osteoarthritis Pain - Pipeline by Centrexion Corporation, H2 2015
Osteoarthritis Pain - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015
Osteoarthritis Pain - Pipeline by Eli Lilly and Company, H2 2015
Osteoarthritis Pain - Pipeline by Elite Pharmaceuticals, Inc., H2 2015
Osteoarthritis Pain - Pipeline by Flexion Therapeutics, Inc., H2 2015
Osteoarthritis Pain - Pipeline by Grunenthal GmbH, H2 2015
Osteoarthritis Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2015
Osteoarthritis Pain - Pipeline by Nektar Therapeutics, H2 2015
Osteoarthritis Pain - Pipeline by Nuvo Research Inc., H2 2015
Osteoarthritis Pain - Pipeline by Pfizer Inc., H2 2015
Osteoarthritis Pain - Pipeline by Phosphagenics Limited, H2 2015
Osteoarthritis Pain - Pipeline by Pozen, Inc., H2 2015
Osteoarthritis Pain - Pipeline by Purdue Pharma L.P., H2 2015
Osteoarthritis Pain - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Osteoarthritis Pain - Pipeline by Rottapharm SpA, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Osteoarthritis Pain Therapeutics - Recent Pipeline Updates, H2 2015
Osteoarthritis Pain - Dormant Projects, H2 2015
Osteoarthritis Pain - Dormant Projects (Contd..1), H2 2015
Osteoarthritis Pain - Dormant Projects (Contd..2), H2 2015
Osteoarthritis Pain - Dormant Projects (Contd..3), H2 2015
Osteoarthritis Pain - Dormant Projects (Contd..4), H2 2015
Osteoarthritis Pain - Discontinued Products, H2 2015
Osteoarthritis Pain - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Osteoarthritis Pain, H2 2015
Number of Products under Development for Osteoarthritis Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report